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Embryonic defence mechanisms 
against glucose-dependent 
oxidative stress require enhanced 
expression of Alx3 to prevent 
malformations during diabetic 
pregnancy
Patricia García-Sanz1,2, Mercedes Mirasierra1, Rosario Moratalla2 & Mario Vallejo1
Oxidative stress constitutes a major cause for increased risk of congenital malformations associated 
to severe hyperglycaemia during pregnancy. Mutations in the gene encoding the transcription factor 
ALX3 cause congenital craniofacial and neural tube defects. Since oxidative stress and lack of ALX3 
favour excessive embryonic apoptosis, we investigated whether ALX3-deficiency further increases 
the risk of embryonic damage during gestational hyperglycaemia in mice. We found that congenital 
malformations associated to ALX3-deficiency are enhanced in diabetic pregnancies. Increased 
expression of genes encoding oxidative stress-scavenging enzymes in embryos from diabetic mothers 
was blunted in the absence of ALX3, leading to increased oxidative stress. Levels of ALX3 increased 
in response to glucose, but ALX3 did not activate oxidative stress defence genes directly. Instead, 
ALX3 stimulated the transcription of Foxo1, a master regulator of oxidative stress-scavenging genes, 
by binding to a newly identified binding site located in the Foxo1 promoter. Our data identify ALX3 
as an important component of the defence mechanisms against the occurrence of developmental 
malformations during diabetic gestations, stimulating the expression of oxidative stress-scavenging 
genes in a glucose-dependent manner via Foxo1 activation. Thus, ALX3 deficiency provides a novel 
molecular mechanism for developmental defects arising from maternal hyperglycaemia.
Maternal pre-gestational diabetes is a major cause for increased risk of embryonic damage and congenital mal-
formations during pregnancy1, 2. Malformations caused by diabetic embryopathy can affect any tissue, but the 
most frequent involve the neural system and the heart3, 4. In humans it has been difficult to establish that embry-
onic malformations are solely a direct effect of glucose toxicity due to the complex metabolic alterations that are 
characteristic of diabetes mellitus. However, animal studies indicate that exposure of developing embryos to high 
glucose levels is sufficient to cause cellular damage leading to severe malformations5, 6.
Congenital neural tube closure and heart defects are frequently observed in mouse or rat embryos developing 
during diabetic pregnancies5–10. Animal models and clinical studies have identified a relatively large number of 
genes associated to these malformations11, 12. However, the mechanisms by which maternal diabetes increases the 
vulnerability of embryos to malformations in humans remain largely elusive.
Many of the embryonic malformations arising as a consequence of gene inactivation or of diabetic gestations 
usually appear with incomplete penetrance10, 12–16, indicating the possible existence of genetic predisposition17–19 
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or the influence of environmental factors15, 19, 20. A major contributor to embryonic malformations associated 
to maternal hyperglycaemia is the increased production of reactive oxygen species (ROS) leading to oxidative 
stress21–23, accompanied by decreased ability of cells to activate antioxidant defence mechanisms24–27. Oxidative 
stress may contribute considerably to excessive apoptosis during development28, 29, which in turn constitutes an 
important determinant for the appearance of malformations in developing embryos5, 29.
The gene encoding the homeodomain transcription factor ALX3 is expressed in mesenchymal cells in mouse 
mid gestation embryos and regulates important developmental processes30–33. Recessive mutations in this gene 
in humans or its deficiency in mice result in craniofacial malformations as well as in cranial neural tube defects 
accompanied by increased apoptosis in the forehead mesenchyme32, 34. In mice, this phenotype exhibits a charac-
teristic incomplete penetrance so that a considerable proportion of Alx3-deficient embryos are apparently normal 
and viable32, 33. In adult mice, Alx3 is expressed in pancreatic islets, and its deficiency leads to apoptosis of islet 
cells and alterations in glucose homeostasis without reaching overt diabetes35, 36. Based on these observations and 
on the association between Alx3-deficiency and apoptosis32, 35, we investigated whether Alx3-deficient embryos 
are more vulnerable to the harmful effects of hyperglycaemia during diabetic pregnancy.
Results
Generation of diabetic pregnancies. In line with our previous findings35, fasting blood glucose levels 
were higher in non-pregnant Alx3-deficient than in wild type females, but they remained with normal range 
(<120 mg/dl) and never reached levels characteristic of overt diabetes, defined as fasting blood glucose concen-
trations higher than 250 mg/dl (Fig. 1A). Since non-pregnant Alx3-deficient females had only a mild hypergly-
caemia, we sought to determine whether pregnancy in these animals was associated with increased basal blood 
glucose levels or severe glucose intolerance. Glucose tolerance tests demonstrated the presence of relatively mild 
glucose intolerance in Alx3-deficient non-pregnant females as compared with wild type non-pregnant controls 
(Fig. 1B). When tests were carried out in pregnant females, we found that wild type animals had developed a 
degree of glucose intolerance similar to that found in Alx3-deficient females (Fig. 1B), consistent with the nor-
mal metabolic adaptations of maternal glucose homeostasis during pregnancy37–39. In contrast, pregnancy did 
not aggravate further the glucose intolerance observed in Alx3-deficient females, which remained similar to the 
glucose intolerance observed in wild type pregnant females (Fig. 1B). In addition, no significant differences were 
found in serum insulin levels of pregnant or non-pregnant Alx3-deficient females as compared to those found 
in wild type animals (Supplementary Table S1). All these data indicate that Alx3-deficient non-pregnant females 
have mild glucose intolerance, but this is not aggravated during pregnancy, being similar to the glucose intol-
erance associated with pregnancy in wild type animals. Therefore, this mild alteration of glucose homeostasis 
cannot be expected to cause embryonic malformations.
Since Alx3-deficient mice do not develop overt diabetes upon pregnancy, we induced diabetic gestations 
by treating female mice with streptozotocin to provoke the selective destruction of pancreatic islets, a widely 
accepted and commonly used method for the study of diabetic embryopathy5–10, 13, 16, 20, 23, 40–43. Pancreatic islet 
destruction by streptozotocin was reflected by the appearance of hyperglycaemia, which was corrected by sub-
cutaneous implantation of insulin pellets (Fig. 1C). Prior to mating, all streptozotocin-treated female mice 
implanted with insulin pellets were checked to have similar fasting glucose levels within normal values, indicat-
ing the effectiveness of insulin released from the pellets (Fig. 1C). After mating, blood glucose levels increased 
progressively as a consequence of pregnancy. One week after the onset of gestation they reached values higher 
than 250 mg/dl, and continued to increase until embryos were extracted for analyses after 10.5 days of gestation 
(Fig. 1C). This severe hyperglycaemia was not due to exhaustion of the insulin content of the pellets, because 
streptozotocin-treated non-pregnant females did not develop hyperglycaemia after insulin pellet implantation 
during a similar period of time.
The average litter size in wild type mice was reduced in the diabetic group relative to the non-diabetic control 
(Fig. 1D). In the case of Alx3-null animals, the number of embryos in non-diabetic pregnancies was lower than in 
non-diabetic wild type pregnancies, but litter size was not reduced further as a consequence of diabetes (Fig. 1D). 
In the diabetic mice, the differences in genotype did not affect the rate of empty decidua or the percentage of 
embryonic resorptions (Table 1).
Increased craniofacial malformations in Alx3-mutant embryos from diabetic pregnancies. We 
broadly identified two morphologically distinct types of embryonic malformations. On the one hand, malforma-
tions typically observed in Alx3-deficient mutants32, affecting the craniofacial mesenchyme and the forehead, or 
defects of the cranial neural tube at the prosencephalic and/or mesencephalic levels. These are referred to in the 
present study as craniofacial malformations. On the other hand, malformations consisting mostly of tail flexion 
defects similar to those defined by Copp et al.44, occasionally including dorsal neural tube closure defects at the 
rhombencephalic or spinal levels. These are referred to in this study as caudal malformations.
No malformations were observed in wild type embryos from non-diabetic pregnancies (Table 2). Consistent 
with previous observations32, a relatively small proportion of Alx3+/− and Alx3−/− embryos developing in 
non-diabetic mothers showed cranial malformations affecting the closure of the cranial neural tube (Table 2 and 
Supplementary Fig. S1).
In diabetic gestations, a proportion of wild type embryos exhibited caudal malformations consisting of tail 
flexion defects (Table 2 and Fig. 2A,B), but no cranial malformations were observed. In the case of Alx3+/− 
embryos, maternal diabetes increased the number of embryos with craniofacial malformations (Table 2, super-
script a; and Fig. 2D and E). We also found caudal malformations affecting the tail in a similar proportion to those 
found in wild type embryos from diabetic mothers (Table 2). The incidence of craniofacial malformations found 
in Alx3+/− embryos was not significantly affected by the genotype of the dams: 6.77% (n = 59) from crossings 
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Figure 1. Induction of diabetic pregnancies in wild type and Alx3-deficient mice. (A) Basal blood glucose 
concentrations after fasting in wild-type (n = 27) and Alx3-deficient (n = 38) female mice. **P < 0.01, Student’s 
t-test. (B) Glucose tolerance tests carried out in fasting wild-type (left panel, blue, n = 21) or Alx3-deficient 
(right panel, red, n = 19) female mice. Both non-pregnant (clear squares) and pregnant mice (solid squares) at 
8.5 days post coitus were tested. *P < 0.05, **P < 0.01 relative to non pregnant wild type animals at each time 
point (ANOVA followed by Bonferroni transformation). No statistically significant differences were found 
between pregnant and non-pregnant Alx3-null females. (C) Blood glucose concentrations after fasting in wild 
type (white circles, n = 22) and Alx3-deficient (black circles, n = 43) female mice. Injections of streptozotocin 
(STZ) and subcutaneous implantation of insulin pellets (Ins) are indicated by arrows. Note that severe 
hyperglycaemia develops again during pregnancy up to 10.5 days of gestation. (D) Number of embryos per litter 
observed in non-diabetic (ND) or diabetic (D) pregnancies at 10.5 days of gestation. The numbers of litters 
were: Alx3+/+, 20 (ND) and 15 (D); Alx3−/−, 19 (ND) and 29 (D). Pregnancies without any embryos were not 
counted for litter size calculations. *p < 0.05; **P < 0.01, Student’s t-test. All values represent mean +− s.e.m.
Genotype
Number 
of dams
Percentage 
of females 
with empty 
decidua
Number of 
implantations
Percentage 
of 
resorptions
Alx3+/+ 22 31.8 (n = 7) 87 10.34 (n = 9)
Alx3−/− 43 27.9 (n = 12) 172
11.62 
(n = 20)
Alx3+/− 44 25 (n = 11) 191 10.47 (n = 20)
Table 1. Pregnancy outcome in diabetic mice.
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between wild type females and Alx3−/− males, and 8.03% (n = 112) from crossings between Alx3−/− females and 
wild type males.
Alx3−/− embryos from diabetic pregnancies showed an even higher proportion of craniofacial malformations 
(Table 2, superscript b). These malformations were considerably more severe than those observed in Alx3+/− 
embryos, generating clearly dysmorphic embryos (Fig. 2G,H). In contrast, the proportion of caudal malfor-
mations was not significantly different from those found in heterozygote or wild type embryos from diabetic 
mothers (Table 2). When compared with non-diabetic pregnancies, maternal diabetes significantly increased 
the number of Alx3−/− embryos with severe craniofacial malformations (Table 2, superscript c). Remarkably, 
the proportion of craniofacial malformations in Alx3+/− or Alx3−/− embryos from diabetic pregnancies was con-
siderably higher than expected if the effects of diabetes and Alx3 deficiency were additive (Table 2, superscripts 
d and e, respectively). A similar result was obtained when the proportion of total malformations (craniofacial 
and caudal together) was considered for each genotype (Table 2, superscripts f and g). In summary, craniofacial 
malformations due to Alx3 inactivation or haploinsufficiency increase considerably in diabetic gestations. This 
synergistic increase indicates that Alx3 deficiency renders the embryos more vulnerable to the teratogenic effects 
of hyperglycaemia.
Increased oxidative stress in Alx3-deficient embryos from diabetic pregnancies. Since high glu-
cose levels favour the generation of ROS in the embryos, we argued that the increase in cranial malformations 
observed in Alx3-deficient embryos from diabetic mothers could reflect a role for ALX3 in the activation of 
defence mechanisms against oxidative stress. To test this hypothesis, we determined whether lack of ALX3 could 
affect the expression levels of genes that encode oxidative stress-scavenging enzymes. The expression of manga-
nese superoxide dismutase (MnSOD), catalase, and glutathione peroxidase-1 (Gpx1) in Alx3-deficient embryos 
from non-diabetic mothers were similar to those observed in non-diabetic wild type embryos (Fig. 3A). Maternal 
diabetes increased the expression of these genes in wild type embryos but not in Alx3-deficient embryos (Fig. 3A). 
Expression of Hif1α, also involved in the defence response to oxidative stress41, 42, was similar in wild type and 
Alx3-deficient embryos from non-diabetic mothers (Fig. 3B). In this case, maternal diabetes resulted in increased 
expression in wild type but not in Alx3-deficient embryos (Fig. 3B).
In addition, expression of neuronal nitric oxygen synthase (NOS) was lower in embryos from diabetic preg-
nancies than in those from non-diabetic pregnancies, but in each of these conditions we found no significant 
differences between wild type and Alx3-deficient embryos (Fig. 3C). In contrast, maternal diabetes increased the 
expression of inducible NOS, but this effect was higher in Alx3-deficient than in wild type embryos (Fig. 3C). 
Consistent with these data, we detected increased nitrotyrosine staining in the head mesenchyme of Alx3-null 
embryos from diabetic pregnancies as compared to wild type embryos (Fig. 3D–F). These results suggest that 
the defence response against oxidative stress in the presence of high glucose levels is impaired in Alx3-deficient 
embryos.
To directly test whether Alx3-deficiency is accompanied by increased oxidative stress, we prepared pri-
mary mouse embryonic mesenchyme (MEM) cells directly from wild type or Alx3 knockout embryos. These 
cells normally express Alx3 abundantly30, 32 and are located in the craniofacial region where malformations in 
Alx3-deficient embryos were found. Using these primary MEM cells we measured ROS production after expo-
sure to low or high concentrations of glucose using fluorescent probes. When cultured in the presence of 5.6 mM 
glucose, a concentration corresponding approximately to euglycaemic levels in vivo, ROS production levels in 
cells from Alx3-deficient embryos were not significantly different from those found in control cells from wild 
type embryos (Fig. 3G). Increasing the concentration of glucose to 30 mM resulted in a significant elevation in the 
intracellular levels of ROS only in Alx3-deficient cells (Fig. 3G).
Then we asked whether lack of ALX3 increases the vulnerability of cells to death by oxidative stress. Initially, 
using DAPI, we determined that exposure to a relatively high concentration of the oxidative stress-inducing 
agent tert-butyl-hydroperoxide (t-BOOH; 300 μM) resulted in a significant increase in the number of non via-
ble primary MEM cells prepared from wild type embryos (Supplementary Fig. S2). Notably, the proportion of 
Genotype
Diabetic 
mother
Number 
of 
embryos 
examined
Number 
of non-
malformed 
embryos
Number of 
embryos with 
craniofacial 
malformations
Number of 
embryos 
with caudal 
malformations
Total 
percentage 
of 
malformed 
embryos
Alx3+/+ No 132 132 0 (0) 0 (0) 0
Alx3+/− No 192 188 4 (2.08) 0 (0) 2.08
Alx3−/− No 86 82 4 (4.65) 0 (0) 4.65
Alx3+/+ Yes 78 74 0 (0) 4 (5.12) 5.12
Alx3+/− Yes 171 147 13 (7.6)a,d 11 (6.43) 14.03f
Alx3−/− Yes 152 115 24 (15.78)b,c,e 13 (8.55) 24.34g
Table 2. Number of malformed or non-malformed embryos at 10.5 days of gestation during non-diabetic 
or diabetic pregnancies. Numbers in parenthesis denote percentage of total. ap < 0.05 relative to Alx3+/− 
embryos from non-diabetic mothers; Fisher’s exact test. bp < 0.05 relative to Alx3+/− embryos from diabetic 
mothers; Fisher’s exact test. cp < 0.05 relative to Alx3−/− embryos from non-diabetic mothers; Fisher’s exact 
test. d,fp < 0.001 relative to Alx3+/− embryos from non-diabetic mothers plus Alx3+/+ embryos from diabetic 
mothers; χ2 test. e,gp < 0.001 relative to Alx3−/− embryos from non-diabetic mothers plus Alx3+/+ embryos from 
diabetic mothers; χ2 test.
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Figure 2. Malformations observed in embryos from diabetic pregnancies after 10.5 days of gestation. (A,B) 
Examples of caudal malformations observed in wild type embryos from diabetic pregnancies. Tail flexion 
defects are indicated by arrowheads. (D,E) Examples of cranial malformations observed in heterozygote Alx3-
deficient embryos from diabetic pregnancies. These include defects of the rostral mesenchyme affecting midline 
closure at the level of the forehead (D, arrowheads), defects at the level of the mesencephalic vesicles (D, arrows) 
and defects of facial mesenchyme expansion (E, arrowheads) affecting the development of the telencephalic 
vesicles (E, arrows). (G,H) Examples of severe malformations found in Alx3-null embryos developing in 
diabetic mothers. Malformations affected several embryonic regions including the forehead mesenchyme, the 
branchial arches and the cranial neural tube (G), or were restricted to severe craniofacial and cranial neural 
tube closure defects (H, arrows). Arrowheads indicate open neural folds. (C,F and I) depict normal wild 
type embryos for comparisons. Scale bars represent 1 mm in all cases except in G (1.5 mm). Abbreviations: 
ba, Branchial arches; FLB, Forelimb bud; HLB, Hind limb bud; m, Mesencephalon; r, Rhombencephalon; t, 
Telencephalic vesicles.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 389  | DOI:10.1038/s41598-017-00334-1
Figure 3. Impaired activation of genes encoding oxidative stress-scavenging enzymes and increased oxidative 
stress in Alx3-deficient embryos developing during diabetic pregnancies. (A–C) Relative levels of mRNA 
extracted from embryos of non-diabetic (ND) or diabetic (D) wild type (white bars) or Alx3-deficient (black 
bars) mice, as assessed by quantitative RT-PCR after 10.5 days of gestation. Shown are mRNAs encoding 
manganese superoxide dismutase (MnSOD), catalase and glutathione peroxidase-1 (Gpx1) (A), Hif1α (B) or 
neuronal (n) or inducible (i) nitric oxide synthase (NOS) (C). *P < 0.05; **P < 0.01; Student’s t-test (n = 7 per 
group). (D and E) Representative sections showing nitrotyrosine immunohistochemistry in the head 
mesenchyme of Alx3+/+ (D) or Alx3−/− (E) embryos from diabetic pregnancies. Arrowheads indicate 
representative examples of nitrotyrosine-positive cells. (F) Quantification of the percentage of nitrotyrosine-
positive cells detected by immunohistochemistry in sections from wild type (white columns) or Alx3-deficient 
(black columns) embryos from diabetic pregnancies. Equivalent mesenchyme regions symmetrically located at 
both left and right sides of each section relative to the midline of the embryo were scored independently. 
Approximately 1000 cells per section from 6 sections obtained from 3 embryos in each group were counted. 
*P < 0.001, Student’s t-test. (G) Quantitation of ROS in control (white bars) or Alx3-deficient (black bars) 
primary MEM cells cultured in the presence of the indicated concentrations of glucose and labelled with the 
fluorescent dye CM-H2DCFDA (n = 6 per group). (H and I) Response of control or Alx3-deficient primary 
MEM cells to t-BOOH treatment. In H, the relative numbers of non-viable cells identified by propidium iodide 
(PI) staining is represented (n = 14 for untreated cell groups; n = 12 for t-BOOH-treated cell groups). In I, ROS 
production as measured by DHE fluorescence is shown (n = 7 for untreated cell groups; n = 6 for t-BOOH-
treated cell groups). In (G–I), *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.05, compared with untreated wild type 
cells. ANOVA followed by Bonferroni test. All values represent mean +− s.e.m.
www.nature.com/scientificreports/
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non-viable MEM cells prepared from Alx3-deficent embryos was significantly higher compared to that of wild 
type cells (Supplementary Fig. S2). To confirm these results, we treated MEM cells with a sub-lethal concentration 
of t-BOOH (100 μM) and determined the proportion of cell death in wild type and Alx3-deficient primary MEM 
cells using propidium iodide. In this case, exposure to t-BOOH only resulted in significantly increased death in 
the case of cells derived from Alx3-deficient embryos, whereas cells from wild type embryos were unaffected 
(Fig. 3H and Supplementary Fig. S2). These experiments indicate that embryonic mesenchyme cells are more 
vulnerable to oxidative stress in the absence of ALX3.
Incubation of cells with DHE indicated that superoxide production did not contribute significantly to the 
elevated ROS pool in Alx3-mutant cells (Fig. 3I). Nonetheless, exposure of cells to t-BOOH (100 μM) generated 
significantly higher levels of the superoxide anion in Alx3-deficient than in wild type MEM cells (Fig. 3I and 
Supplementary Fig. S2).
ALX3 regulates the expression of Foxo1. Impaired expression of defence genes against oxidative stress 
leading to excess ROS production in Alx3-deficient embryos under hyperglycaemic conditions could reflect a 
possible role for ALX3 in the regulation of the transcriptional transactivation of these genes. Consistent with 
this hypothesis, we found that maternal diabetes results in increased expression of Alx3 mRNA in wild type 
embryos (Fig. 4A), and that the levels of ALX3 protein were elevated when primary MEM cells were cultured 
in the presence of high rather than low glucose (Fig. 4B,C), indicating that Alx3 is a glucose-responsive gene in 
mouse embryos. However, in silico analysis (http://www.dcode.org) of 10 kb regions of the promoters of the genes 
encoding MnSOD, catalase, Gpx1, and Hif1α did not predict the existence of binding sites for ALX3, character-
ized by the existence of a consensus TAAT motif45. We then argued that ALX3 could regulate the expression of 
these genes indirectly, by stimulating the expression of key transcription factors known to activate the oxidative 
stress defence response such as Nrf246, Foxo1 and Foxo416, 47, 48.
Maternal diabetes reduced the expression of Nrf2 to a similar degree in wild type and Alx3-null embryos, 
making it an unlikely candidate as a target for regulation by ALX3 (Fig. 4D). On the contrary, maternal diabetes 
increased the expression of Foxo1, but this response was significantly blunted in Alx3-null embryos (Fig. 4D). 
Expression of Foxo4 was also increased in embryos developing in diabetic pregnancies, but the difference between 
Alx3-deficient and wild type embryos was not statistically significant (Fig. 4D). Thus, these experiments indicate 
that lack of ALX3 impairs induced expression of Foxo1 in diabetic pregnancies, and suggested that this gene could 
be a direct target for regulation by ALX3.
Using in silico analysis, we identified a potential target site for binding by ALX3 in the Foxo1 promoter located 
between nucleotides –826 to –809 relative to the transcription initiation site (Fig. 4E). Therefore, we investigated 
whether ALX3 regulates the expression of Foxo1 directly. Direct binding of ALX3 to the target Foxo1 promoter 
site was confirmed by electrophoretic mobility shift assays using nuclear extracts from primary MEM cells from 
wild type embryos. Sequence specificity of DNA–protein complexes was determined by competition with unla-
belled oligonucleotides added in excess to the binding reaction, and the presence of ALX3 in these complexes 
was confirmed by the addition of an ALX3 antibody (Fig. 4F). Using transfections of a luciferase reporter under 
the control of the Foxo1 promoter in Hela or in primary MEM cells from Alx3-null embryos, we found that 
overexpression of Alx3 resulted in increased luciferase activity only when the target site in the Foxo1 promoter 
was present (Fig. 4G and H), thus supporting the notion that ALX3 transactivates the Foxo1 promoter by binding 
specifically to this site.
Chromatin immunoprecipitation assays using primary MEM cells from wild type embryos demonstrated that 
ALX3 binds to this region of the endogenous Foxo1 gene in the context of native chromatin in vivo when cells 
are incubated in high glucose (30 mM), but not in the presence of low glucose (2.8 mM) (Fig. 4I). Using electro-
phoretic mobility shift assays, binding of ALX3 to the target site of the Foxo1 promoter was only detected when 
primary MEM cells were cultured in high rather than low glucose concentrations (Fig. 4J). Consistent with these 
findings, glucose induced an increase in the levels of FOXO1 protein in cells from wild type embryos, but not in 
cells from Alx3-null embryos (Fig. 4E).
The existence of a possible functional relationship between increased Alx3 and Foxo1 levels in the context of 
abnormally elevated concentrations of glucose was further investigated in primary MEM cells. We argued that if 
glucose-induced ALX3 is responsible for the increased expression of Foxo1, it could be expected that in cells lack-
ing ALX3, expression of Foxo1 would not occur in response to increased concentrations of glucose. In turn, this 
would lead to impaired glucose-dependent expression of genes encoding oxidative stress detoxifying enzymes. 
To test this hypothesis, primary MEM cells were prepared from Alx3-null or control wild type embryos from 
non-diabetic pregnancies.
Glucose induced the expression of Alx3 in wild type primary MEM cells (Fig. 5A), confirming our initial 
results in embryos. Glucose also induced the expression of Foxo1 and Foxo4 in these cells (Fig. 5B). In contrast, 
in cells from Alx3-deficient embryos the induction of Foxo1 expression by glucose was inhibited, whereas that 
of Foxo4 was unaffected (Fig. 5B). In addition, in serum starved conditions expression of Foxo1 was significantly 
decreased in Alx3-deficient MEM cells, but addition of insulin did not result in significant modification of Foxo1 
expression regardless of whether ALX3 was present or not (Fig. 5C). Thus, these experiments indicate that ALX3 
regulates the Foxo1 gene and is specifically required for glucose induced Foxo1 expression.
Furthermore, expression of mRNAs encoding MnSOD, catalase and Gpx1 was induced by glucose in MEM 
cells derived from wild type embryos, but not in those derived from Alx3-deficient embryos (Fig. 5D). Taken 
together, these experiments support the notion that high glucose concentrations induce the expression of Alx3, 
which in turn stimulates expression of Foxo1, and this subsequently that of genes encoding oxidative stress detox-
ifying enzymes.
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Figure 4. Regulation of the Foxo1 promoter by ALX3. (A) Quantitative RT-PCR of Alx3 mRNA in embryos 
from non-diabetic (ND) or diabetic (D) wild type mice (n = 7 per group). (B) Western blot showing ALX3 in 
primary MEM cells cultured in the indicated concentrations of glucose. (C) Densitometric measurements of 
ALX3 bands relative to actin bands from three western blots similar to that shown in B. D) Quantitative RT-
PCR of Nrf2, Foxo1 or Foxo4 mRNAs, extracted from embryos of non-diabetic (ND) or diabetic (D) wild type 
(white bars) or Alx3-deficient (black bars) mice; n.s., non-significant (n = 7 per group). (E) ALX3-binding site 
and its position in the mouse Foxo1 promoter. (F) Electrophoretic mobility shift assays showing the binding of 
proteins from nuclear extracts of primary MEM cells to an oligonucleotide probe containing the sequence 
indicated in E. The absence (−) or presence of competing or nonspecific competing (NSC) oligonucleotides at 
the indicated fold molar excess, or of an ALX3 antibody or control IgG, is depicted on top. Arrows indicate 
complexes containing ALX3. (G,H) Relative luciferase activity elicited in Hela (G) or primary Alx3-defcient 
MEM (H) cells co-transfected with the reporter plasmids Foxo1T81Luc or control pT81Luc, and an ALX3 
expression plasmid (n = 5). (I) Quantitative PCR amplification of Foxo1 chromatin immunoprecipitated with 
anti-ALX3 antiserum or with control non-immune rabbit serum (NRS) from primary MEM cells isolated from 
wild type mice and cultured in the presence of the indicated concentrations of glucose. Horizontal lines 
represent the mean (n = 4). (J) Electrophoretic mobility shift assays showing binding of nuclear extracts from 
primary MEM cells cultured at the indicated concentrations of glucose to the Foxo1 promoter site indicated in 
E. Arrows indicate the presence of ALX3. (K) Western blot showing FOXO1 in primary wild type (left panels) 
or Alx3-deficient (right panel) MEM cells cultured in the indicated concentrations of glucose. A representative 
example of three independent experiments with similar results is depicted. Uncropped blots are provided in 
Supplementary Fig. S5. Except in I, all values represent mean +− s.e.m. *P < 0.05, **P < 0.01, Student’s t-test.
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Altered developmental gene expression in Alx3-deficient embryos from diabetic pregnan-
cies. Finally, we investigated whether the alterations observed in Alx3-deficient embryos from diabetic 
pregnancies correlated with altered expression of genes controlling embryonic programs for mesenchyme devel-
opment. We chose representative examples of genes whose deficiencies have been documented to be associated 
with developmental defects with partial penetrance. We found that in diabetic pregnancies, expression of Ap249, 
Bmp450 and Pdgfrα51 was reduced in Alx3-deficient embryos as compared with wild type embryos (Fig. 6). In con-
trast, we did not find significant changes in the expression of Gcn5, which encodes a histone acetyltransferase not 
involved in mesenchyme development52, 53. No differences in the expression of these genes were found between 
wild type and Alx3-null embryos from non-diabetic pregnancies. Thus, these results show that impaired expres-
sion of some developmental genes only appears when both Alx3-deficiency and diabetes are present.
Discussion
Our work indicates that Alx3 confers protection against oxidative stress produced by glucose in embryonic cells, 
thus contributing to the prevention of the teratogenic effects of hyperglycaemia during diabetic pregnancy. 
Glucose up-regulates the expression of Alx3, which in turn stimulates the expression of Foxo1 and the expres-
sion of genes encoding oxidative stress-scavenging enzymes as alfa defence mechanism against excess ROS gen-
erated by hyperglycaemia. This notion is consistent with the observation of activated expression of oxidative 
stress-scavenging genes in wild type but not in Alx3-deficient embryos developing in diabetic mothers. Although 
we cannot rule out the existence of epigenetic changes on the target promoters, our data strongly support the 
notion that Foxo1 activation in response to glucose is due to increased expression of ALX3 stimulated by glucose 
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Figure 5. Impaired response to glucose in Alx3-deficient cells. (A) Relative levels of Alx3 mRNA in primary 
MEM cells obtained from wild type mice cultured in the presence of the indicated concentrations of glucose 
(n = 5). (B) Relative levels of Foxo1 and Foxo4 mRNA in primary MEM cells obtained from wild type (white 
bars) or Alx3-deficient (black bars) embryos cultured in the presence of the indicated glucose concentrations 
(n = 7 per group). (C) Relative levels of Foxo1 mRNA in primary MEM cells from wild type (white bars) or 
Alx3-deficient (black bars) embryos cultured in the presence of 0.5% FBS without (−) or with (+) insulin 
(100 nM) (n = 5 per group). (D) Relative levels of MnSOD, catalase and Gpx1 mRNA in primary MEM cells 
from wild type (white bars) or Alx3-deficient (black bars) embryos cultured in the indicated glucose 
concentrations (n = 7 per group). All data obtained by quantitative RT-PCR. In all cases, values represent mean 
+− s.e.m. *p < 0.05, **p < 0.01, Student’s t-test.
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itself, and not to a change in the binding efficiency of this transcription factor. That is, in the presence of low 
concentrations of glucose, ALX3 levels are low, and therefore Foxo1 promoter occupancy at the specific bind-
ing site described in this study is low, thus leading to reduced transactivation. On the contrary, in the presence 
of high concentrations of glucose, ALX3 levels a high, favoring binding to the Foxo1 promoter and increasing 
transactivation.
The mechanism by which glucose stimulates the expression of Alx3 is unknown, but it appears not to be spe-
cific of embryonic cells. In the adult organism, expression of Alx3 in glucagon-producing cells of the pancreatic 
islets is also stimulated by glucose. In that case, increased levels of ALX3 in response to elevated glucose result in 
transcription factor interactions that lead to down-regulation of the glucagon gene, closing a negative feed back 
loop important for the maintenance of glucose homeostasis36. Thus, Alx3 emerges as an important glucose sensor 
to protect the organism against the harmful effects of hyperglycaemia. In the present study, Alx3 deficiency in 
mouse embryos developing in diabetic mothers resulted in increased oxidative stress, rendering them more vul-
nerable to congenital malformations.
The increase in craniofacial but not caudal malformations observed in Alx3-deficient embryos developing 
in diabetic pregnancies is in good agreement with the strong expression of Alx3 in the forehead mesenchyme of 
wild type embryos30, 32, and indicate that in the absence of Alx3 the mesenchyme cells from this region become 
vulnerable to the harmfull effects of high glucose concentrations. In line with this reasoning, the most severe mal-
formations observed in Alx3−/− embryos from diabetic mothers could reflect, in addition, increased vulnerability 
of cells located in other tissues in which Alx3 is normally expressed, such as the lateral mesoderm or the serous 
membranes that separate internal organs30, 32. Thus, the significant increase in cranial malformations observed 
when Alx3 deficiency and diabetes are present together reflects the absence of a protective role for Alx3 against 
the teratogenic effects of glucose.
Numerous studies have established a link between oxidative stress and diabetic embryopathy7, 21, 22, 54. In 
Alx3-deficient embryonic cells, excess oxidative stress is a consequence of increased production of ROS, as well as 
of reactive nitrogen species evidenced by elevated nitrotyrosine content and expression of inducible NOS, which 
has been implicated in the pathogenesis of embryonic malformations induced by maternal diabetes43, 55.
Stimulation of the expression of genes encoding oxidative stress-scavenging enzymes has been proposed to 
act as a mechanism of defence against damage induced by ROS during diabetic pregnancy26, 27. Our data indicate 
that Alx3 is important for this mechanism of defence for three reasons. First, elevations in glucose concentrations 
stimulate the expression of Alx3, which therefore serves as a glucose sensor to initiate a transcriptional program 
of defence. Second, glucose-induced stimulation of Alx3 expression is required for the stimulation of oxidative 
stress-scavenging genes. And third, Alx3 is required for the glucose-induced expression of Foxo1, a well-known 
stimulator of oxidative stress-scavenging gene expression during the antioxidant defence response16, 47, 48, 56, 57.
We propose that the ALX3-dependent stimulation of the oxidative stress defence response is mediated by 
an indirect transcriptional activation pathway involving Foxo1, because we did not find DNA sequence motifs 
corresponding to putative ALX3 binding sites in the promoter regions of any of the target genes examined. Taken 
together, all these data support the proposal that high glucose concentrations favouring the generation of oxida-
tive stress stimulate the expression of Alx3, which in turn activates the expression of Foxo1, thus stimulating the 
expression of the genes encoding ROS scavenging enzymes47, 48.
The observation that maternal diabetes induced the expression of Hif1α in wild type but not in Alx3-deficient 
embryos is in agreement with studies showing an increase in Hif1α mRNA and protein levels in diabetes-exposed 
mouse embryos16, 41. Although the regulation of many of the cellular functions of HIF1α has been described to 
operate at the protein level, increasing evidence indicates that transcriptional control of its expression plays an 
important role58. In this regard, Hif1α expression increases in response to glucose via regulation at the promoter 
level59. During diabetic pregnancy both hypoxic and oxidative stress occur concomitantly60 and stimulate HIF1α 
function61. The increased expression of Hif1α in embryos developing during diabetic pregnancies provides a 
defence mechanism to protect them from the toxic effects of glucose16, 41. Although ALX3 does not appear to 
regulate Hif1α directly, our data support the notion that the stimulated increase of ALX3 in response to elevated 
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mRNA encoding representative developmentally regulated genes in wild type (white bars) or Alx3-null (black 
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glucose levels plays an important role to coordinate the protective response of the embryo to maternal diabetes 
because Alx3-deficiency significantly impairs the enhanced expression of embryonic Hif1α and oxidative stress 
detoxifying genes during diabetic pregnancy.
Maternal hyperglycaemia alters gene expression patterns in the embryo, and this may play an important 
role in the pathogenesis of congenital defects during diabetic pregnancy10, 16, 19, 62, 63. Alx3 deficiency in embryos 
exposed to high glucose concentrations in utero results in decreased expression of Ap2, Bmp4 and Pdgfrα, chosen 
as representative examples of genes whose deficiencies cause congenital defects that are similar to some of the 
craniofacial defects found in Alx3-deficient embryos. AP2 is expressed in mesenchyme cells that are important 
craniofacial and neural development49, 64. BMP4 and PDGFRα are signalling molecules that control different 
aspects of craniofacial mesenchyme differentiation51, 65. Importantly, we only detected significant changes in the 
expression of Ap2, Pdgfrα and Bmp4 when both Alx3 deficiency and maternal diabetes were present together. 
Although many other genes are likely to be affected by maternal diabetes16, 19, 62, 63, these changes represent indi-
cations that Alx3 is important for the protection of transcriptional and cell signalling programs that are critical 
for embryonic development from the noxious effects of hyperglycaemia. Interestingly, Gcn5 expression was not 
affected by Alx3 deficiency even in the presence of maternal diabetes. Since Gcn5 deficiency results in embryonic 
neural tube defects without affecting mesenchyme development53, this observation suggest that the impact of 
maternal diabetes is greater in Alx3-deficient mesenchyme cells than in other cell types in which Alx3 is not 
normally expressed.
We looked for evidence of altered gene expression in Alx3-deficient embryos from diabetic pregnancies show-
ing no major malformations to avoid the detection of changes that could be attributable to alterations in cellular 
composition associated to dysmorphogenesis. This is important because incomplete penetrance of congenital 
malformations constitutes a common feature of birth defects induced by maternal diabetes, so that a proportion 
of embryos develop normally despite the detection of significant changes in gene expression16, 63. This may be due 
to increased variability in gene expression levels induced by maternal diabetes, so that defects would only appear 
when expression of certain genes fall below a given threshold63. In this context, Alx3 deficiency would render the 
embryos prone to the appearance of overt developmental alterations by increasing permissively the magnitude of 
these changes. Therefore, changes in the expression of genes observed in Alx3-deficient embryos from diabetic 
mothers do not necessarily identify direct targets of regulation by ALX3. Instead, these changes reflect a role for 
ALX3 as a protective genetic buffer to temper the effects of hyperglycaemia on gene expression levels during a 
critical period of development.
In conclusion, our data reveal the existence of a novel defence mechanism to prevent congenital malformations 
due to oxidative stress during diabetic pregnancies. In this mechanism, Alx3 participates as a glucose-responsive 
gene required for the activation of Foxo1 and the subsequent stimulation of oxidative stress-scavenging genes. In 
humans, recessive ALX3 mutations have been shown to cause congenital craniofacial alterations34. Thus, taken 
together in the context of the present study, loss of function mutations in Alx3 emerge as putative determinants 
for increased risk of congenital craniofacial malformations associated with diabetes during pregnancy.
Methods
Mice. Alx3-deficient mice33 were maintained in a C57BL/6 J × FVB/N background by heterozygote inter-
crosses and were genotyped using PCR as described35. Experimental protocols involving mice were approved 
by the institutional bioethics committees on research animal care (IIBM Committee on Human and Animal 
Experimentation and CSIC Ethics Committee), and are in accordance with the requirements of Spanish (RD 
53/2013) and European Union (63/2010/EU) legislation.
Induction of insulin-dependent diabetes and pregnancy. Insulin-dependent diabetes and pregnancy 
in mice were induced largely as described40. Briefly, 8–10 week old wild type or Alx3−/− female mice were treated 
with streptozotocin (Sigma-Aldrich, Madrid, Spain; 75 mg/kg, i.p.) for four consecutive days to destroy pancre-
atic islets. The rise in blood glucose levels after the injections was monitored with a glucometer (Glucotrend Soft 
Test System; Boehringer Ingelheim, Mannheim, Germany) using tail blood, and hyperglycaemia was controlled 
by subcutaneous implantation of sustained-release insulin pellets (LinShin, Toronto, Ontario, Canada). Stable 
recovery of blood glucose levels after pellet implantation was monitored regularly. After confirming that blood 
glucose levels were stable for 2–3 weeks, females were mated with non-diabetic wild type or Alx3−/− male mice. 
Noon on the day in which a vaginal plug was found was considered to be day 0.5 of gestation. Blood glucose levels 
were monitored from this time on every three days. On gestation day 10.5, pregnant mice were killed by cervical 
dislocation and the embryos were extracted for analyses. As a control, a different group of streptozotocin-treated 
females received insulin pellets but were not mated to males. These non-pregnant females did not develop diabe-
tes during a similar period of time. Islet destruction by streptozotocin was confirmed in histological sections of 
the pancreases processed for insulin immunofluorescence (Supplementary Fig. S3).
Glucose tolerance test and insulin determinations. Glucose levels were measured with a glucometer 
using blood obtained by puncture of the tip of the tail after an overnight fasting period. After measuring baseline 
glucose levels, mice were injected with glucose (2 g/kg, i.p.), and blood was tested 15, 60 and 120 minutes after 
the injection. Glucose tolerance tests were carried out both before pregnancy and 8.5 days after coitus. Fasting 
(4 hours) serum insulin was measured before pregnancy and 10.5 days post coitus using an ELISA kit (Crystal 
Chem, Downers Grove, IL, USA).
Immunohistochemistry. Cryostat sections (10 μm) of embryos were processed for anti-nitrotyrosine 
immunohistochemistry using a specific antibody (Millipore, Billerica, MA, USA; Ref. 06-284, 1:1000 dilution). 
Immunodetection was carried out with a secondary biotinylated goat anti-rabbit antiserum (Bio-Rad) using 
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immunoperoxidase staining. The expression of nitrotyrosine was scored by quantifying the number of positive 
cells per region of interest from digital images using NIH ImageJ software. In all sections regions of interest 
located both on the left and right sides of the embryo were scored independently. Counterstaining was carried out 
with haematoxylin. Immunofluorescence on pancreas sections with an insulin antibody (Ab7842, Abcam; 1/100 
dilution) was performed as described35.
Mouse embryonic mesenchyme cells. Primary MEM cells were obtained from the forehead mesen-
chyme of embryos taken from time-pregnant females at gestation day 10.5 as described31. This location and ges-
tation time were chosen to maximize the number of cells expressing Alx330, 32. Briefly, the first branchial arch and 
the most rostroventral part of the forehead mesenchyme of each embryo was dissected and pieces from several 
embryos of the same genotype were pooled. Once dispersed, cells were incubated in standard DMEM containing 
10% FBS and split a maximum of three times. In one set of experiments, primary MEM cells were incubated in 
medium containing 2.8 mM glucose overnight. After this, the medium was replaced with fresh medium con-
taining either 2.8 mM, 16 mM or 30 mM glucose, and the incubation proceeded for another 24 hours until cells 
were harvested. In a different set, cells were incubated in DMEM containing 0.5% FBS and 0.5% BSA, and insulin 
(Human recombinant, Sigma I2643) was added to a concentration of 100 nM overnight.
Intracellular ROS measurement by fluorescence-activated cell sorting. ROS levels in pri-
mary MEM cells cultured in different concentrations of glucose or treated with t-BOOH (Sigma-Aldrich) 
were determined after incubation for 30 minutes in the dark with the fluorescent probes 5-chloromethyl-2′,7
′-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA, 0.5 μM; Invitrogen) or dihydroethidium 
(DHE, 2 μM; Invitrogen). CM-H2DCFDA is a general ROS indicator that detects primarily hydrogen peroxide, 
whereas DHE specifically detects the superoxide anion66. Cell viability was assessed by measuring the plasma 
membrane permeability to 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; 1 μg/ml, ThermoFisher 
Scientific/Molecular Probes, Waltham, MA, USA) or to propidium iodide (1 μg/ml, Sigma-Aldrich, St. Louis, 
MO)67. Fluorescence (10,000 cells/sample) was measured by flow cytometry using a FACS Aria I flow cytometer 
(Becton–Dickinson, Franklin Lakes, NJ, USA). All measurements were carried out in duplicate.
Quantitative RT-PCR. Total RNA from MEM cells or from individual embryos was extracted using the 
Illustra RNAspin kit (GE Healthcare Europe, Barcelona, Spain). Embryos showing major malformations were 
not used for mRNA determinations to avoid artefacts arising directly from embryonic dysmorphogenesis16. 
Determinations were carried out in the Core Facilities of the Genomics Unit at the Scientific Park of Madrid 
(http://fpcm.es). Quantitative PCR for Alx3 was performed with TaqMan Assay-on-Demand primers and the 
Taqman Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Alcobendas, Madrid, Spain). In 
other cases, SYBR Green detection was used with Power SYBR Green PCR Master Mix (Applied Biosystems) and 
the primers indicated in Supplementary Table S2. PCR reactions were performed in triplicate and values were 
normalized to Gapdh mRNA levels using the double delta Ct method. Stability of Gapdh as a reference for nor-
malization was confirmed using geNorm68, and results are shown in Supplementary Fig. S4.
Western blot. Western blots from primary MEM cell lysates were performed as described31. Antibodies for 
ALX3 (1:5000 dilution)31, FOXO1 (L27, 1:1000 dilution; Cell Signalling Technology, Beverly, MA, USA) and 
β-actin (AC-15, 1:10000 dilution; Sigma-Aldrich) were used for detection. Where indicated, films were scanned 
and densitometry measurements of bands were performed using ImageJ software (http://rsbweb.nih.gov/ij/).
Chromatin immunoprecipitation assays. Chromatin immunoprecipitation assays were performed 
as described69. Quantitative PCR was performed using oligonucleotide primers that amplify a fragment of the 
mouse Foxo1 gene spanning nucleotides −880 to −751 relative to the transcription initiation site. Their sequence 
is as follows: Forward, 5′-TGCGACTTCAACACCTCATC-3′; reverse, 5′-CGGTGTGGTGGCTAAAGAGT-3′. 
SYBR Green detection was used with Power SYBR Green PCR Master Mix (Applied Biosystems). Data were cal-
culated as fold enrichment relative to input.
Electrophoretic mobility shift assays. Nuclear protein extracts from primary MEM 
cells were prepared and electrophoretic mobility shift assays were performed as described69. The 
sequence of the oligonucleotide from the mouse Foxo1  promoter is as follows (sense strand): 
5′-GATCCAGTTAAACTTAATTAGGGGTAATAAAGTGA-3′. For supershift experiments, nuclear extracts 
were preincubated with an ALX3 antibody (ab64985, Abcam, Cambridge, MA, USA) before the addition of the 
labelled probe.
Plasmids and transfections. A segment of the mouse Foxo1 gene promoter spanning nucle-
otides −880 to −751 relative to the transcription initiation site was amplified by PCR using the fol-
lowing pr imers :  For ward,  5 ′-CAGGATCCTGCGACT TCAACACCTCATC-3 ′ ;  and reverse, 
5′-CAAAGCTTCGGTGTGGTGGCTAAAGAGT-3′. The resulting fragment was cloned into the luciferase 
reporter plasmid pT81Luc70 to yield Foxo1T81Luc. The expression vector pcDNA3-Alx3 has been described 
elsewhere45.
HeLa cells or primary MEM cells prepared from Alx3-deficient embryos were seeded into 24-well plates at a 
density of 7 × 104 cells per well and incubated overnight. Cells were transfected for 4 hours with Lipofectamine 
(Invitrogen), using 500 ng of luciferase reporter plasmid, 50 ng of pRL-TK-Renilla and pcDNA3-Alx3 or control 
pcDNA3 plasmids. Luciferase and Renilla activities were measured using a commercial Dual Luciferase Assay 
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kit (Promega, Madrid, Spain) 48 hours after transfection. The reporter plasmid RSV-Luc was used as an inde-
pendent standard for normalization, and efficiencies were corrected by using the Renilla luciferase assay system 
(Promega). All transfections were carried out in duplicates.
Statistical analysis. The incidence of malformations was analysed by the Fisher exact test. The presence of 
synergism between hyperglycaemia and Alx3 deficiency was tested by comparing observed and expected malfor-
mation frequencies using χ2 test. All other data are expressed as mean ± s.e.m., and were analysed by Student’s 
t-test or two-way ANOVA followed by Bonferroni transformation, using Package GraphPad Prism 6 software.
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